<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=202310041 808 13&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U- NVu8003KrCpq8yLQC -<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20231004180813&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 10 月 4 日，星期三 22:08:15 +0000</lastbuilddate><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>肠溶阿司匹林与非包衣阿司匹林在心血管疾病患者中的有效性和安全性：ADAPTABLE 随机临床试验的二次分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37792369/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在 ADAPTABLE 随机临床试验的事后二次分析中，无论剂量如何，与未包衣阿司匹林相比，肠溶阿司匹林与显着较高的心肌梗塞、中风或死亡风险或较低的出血风险无关。虽然不能排除肠溶阿司匹林可以减少出血。需要更多的研究来确认肠溶阿司匹林制剂或更新的制剂是否会改善... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 10 月 4 日。doi：10.1001/jamacardio.2023.3364。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：临床医生建议在冠心病二级预防中使用肠溶阿司匹林来减少胃肠道出血，尽管研究表明肠溶阿司匹林制剂与未包衣阿司匹林制剂相比会降低血小板抑制作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估服用肠溶阿司匹林与未服用肠溶阿司匹林是否与有效性或安全性结果相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设以患者为中心的临床研究网络。患者从 2016 年 4 月 19 日至 2020 年 6 月 30 日期间入组，并随机分配接受高剂量（325 毫克）和低剂量（81 毫克）每日阿司匹林。本分析评估了有效性和在基线报告阿司匹林配方的参与者中，肠溶阿司匹林与非包衣阿司匹林的安全性。数据分析时间为2019年11月11日至2023年7月3日。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预：根据基线时自我报告的阿司匹林配方对适应性强的参与者进行重新分组，中位随访时间 (IQR) 为 26.2 (19.8-35.4) 个月。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结局和指标：主要有效性终点是心肌梗死、卒中或全因死亡复合终点的累积发生率，主要安全性终点是主要出血事件（因使用血液而导致出血事件住院）使用未调整的多变量 Cox 比例风险模型，比较了服用肠溶衣或未包衣阿司匹林的参与者在中位随访中主要有效性和主要安全性终点的累积发生率。所有分析均针对意向性- 治疗人群。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：ADAPTABLE 中使用的基线阿司匹林配方由 10 678 名参与者（中位 [IQR] 年龄，68.0 [61.3-73.7] 岁；7285 名男性 [68.2%]）自行报告，其中 7366 名 (69.0%) 进入了服用阿司匹林配方的患者阿司匹林和 3312 (31.0%) 服用未包衣阿司匹林。有效性（调整后风险比 [AHR]，0.94；95% CI，0.80-1.09；P = .40）或安全性（AHR，0.82；95% CI， 0.49-1.37；P = .46) 发现肠溶阿司匹林和非包衣阿司匹林队列之间的结果。在肠溶阿司匹林和非包衣阿司匹林中，阿司匹林剂量与有效性无关（肠溶阿司匹林 AHR，1.13；95% CI，0.88-1.45 和未包衣阿司匹林 AHR，0.99；95% CI，0.83-1.18；相互作用 P = .41）或安全性（肠溶阿司匹林 AHR，2.37；95% CI，1.02-5.50 和未包衣阿司匹林 AHR，0.89 ；95% CI，0.49-1.64；交互作用 P = .07)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在 ADAPTABLE 随机临床试验的事后二次分析中，无论剂量如何，与未包衣阿司匹林相比，肠溶阿司匹林与显着较高的心肌梗塞、中风或死亡风险或较低的出血风险无关。尽管不能排除肠溶阿司匹林可以减少出血，但仍需要更多研究来证实肠溶阿司匹林制剂或新制剂是否会改善该人群的预后。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试验注册：ClinicalTrials.gov 标识符：NCT02697916。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37792369/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37792369</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3364>10.1001/jamacardio.2023.3364</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37792369</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator>琥珀史莱姆</dc:creator><dc:creator>马克·B·埃夫隆</dc:creator><dc:creator>阿曼达·斯特宾斯</dc:creator><dc:creator>丽莎·M·鲁克</dc:creator><dc:creator>纪尧姆·马奎斯·格拉维尔</dc:creator><dc:creator>丹尼尔·穆尼奥斯</dc:creator><dc:creator>理查德·N·雷</dc:creator><dc:creator>卡迈勒·古普塔</dc:creator><dc:creator>卡尔·佩平</dc:creator><dc:creator>桑迪普·K·贾恩</dc:creator><dc:creator>萨凯特·吉罗特拉</dc:creator><dc:creator>杰弗里·惠特尔</dc:creator><dc:creator>凯瑟琳·P·本齐格</dc:creator><dc:creator>彼得·M·法雷希</dc:creator><dc:creator>柯克·诺尔顿</dc:creator><dc:creator>塔玛·S·波隆斯基</dc:creator><dc:creator>马修·T·罗伊</dc:creator><dc:creator>拉塞尔·罗斯曼</dc:creator><dc:creator>罗伯特·哈林顿</dc:creator><dc:creator>W·斯凯勒·琼斯</dc:creator><dc:creator>阿德里安·埃尔南德斯</dc:creator><dc:date>2023-10-04</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>肠溶阿司匹林与非包衣阿司匹林在心血管疾病患者中的有效性和安全性：ADAPTABLE 随机临床试验的二次分析</dc:title><dc:identifier>下午:37792369</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3364</dc:identifier></item><item><title>射血分数保留的心力衰竭患者是否需要姑息治疗？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37792359/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 10 月 4 日。doi：10.1001/jamacardio.2023.3360。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37792359/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37792359</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3360>10.1001/jamacardio.2023.3360</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37792359</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator>莎拉·戈弗雷</dc:creator><dc:creator>安巴里什·潘迪</dc:creator><dc:creator>海德尔·J·瓦莱奇</dc:creator><dc:date>2023-10-04</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>射血分数保留的心力衰竭患者是否需要姑息治疗？</dc:title><dc:identifier>下午:37792359</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3360</dc:identifier></item><item><title> 50 多岁的女性，静脉内肿块延伸至右心室</title><link/>https://pubmed.ncbi.nlm.nih.gov/37792355/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 10 月 4 日。doi：10.1001/jamacardio.2023.3385。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37792355/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37792355</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3385>10.1001/jamacardio.2023.3385</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37792355</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator>李洁华</dc:creator><dc:creator>李全明</dc:creator><dc:creator>常熟</dc:creator><dc:date>2023-10-04</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>50 多岁的女性，静脉内肿块延伸至右心室</dc:title><dc:identifier>下午:37792355</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3385</dc:identifier></item><item><title>内皮鞘脂生物合成在脑血管稳态中的重要作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37791485/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 10 月 4 日。doi：10.1161/CIRCRESAHA.123.323183。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37791485/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37791485</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323183>10.1161/CIRCRESAHA.123.323183</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37791485</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator>路易莎·鲁比内利</dc:creator><dc:creator>莉迪亚·加西亚-博尼拉</dc:creator><dc:creator>琳达·萨塞特</dc:creator><dc:creator>安娜·坎塔卢波</dc:creator><dc:creator>本杰明戈雅</dc:creator><dc:creator>叶占士</dc:creator><dc:creator>约瑟夫·安拉瑟</dc:creator><dc:creator>科斯坦蒂诺·亚德科拉</dc:creator><dc:creator>朱塞佩·法拉科</dc:creator><dc:creator>安娜丽塔·迪·洛伦佐</dc:creator><dc:date>2023-10-04</dc:date><dc:source>流通研究</dc:source><dc:title>内皮鞘脂生物合成在脑血管稳态中的重要作用</dc:title><dc:identifier>下午：37791485</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323183</dc:identifier></item><item><title>心脏骤停后肾损伤的血压和氧气目标</title><link/>https://pubmed.ncbi.nlm.nih.gov/37791480/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description>结论：在院外心脏骤停后复苏的昏迷患者中，分配到低平均动脉血压和自由氧目标组合的患者发生轻度 AKI 的风险显着增加。就更严重的 AKI 阶段或其他与肾脏相关的不良后果而言，肌酐在出院 1 年后已恢复正常。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 10 月 4 日。doi：10.1161/CIRCULATIONAHA.123.066012。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：急性肾损伤 (AKI) 是院外心脏骤停的常见且严重的并发症。复苏后血压和氧合护理目标对 AKI 发生的重要性尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：这是一项随机 2×2 析因试验的子研究，其中 789 名因推测心脏原因发生院外心脏骤停且自主循环持续恢复的昏迷成年患者被随机分配至目标平均动脉组血压为 63 或 77 mm Hg。患者同时被随机分配至动脉氧分压 (Pao <sub>2</sub> ) 9 至 10 kPa 的限制性氧合目标或 Pao <sub>2</sub>为 13 至 14 的自由氧合目标kPa。本研究的主要结果是根据 KDIGO（肾脏疾病：改善全球结果）分类，存活至少 48 小时的患者 (N=759) 出现 AKI。对分配给高血压和自由氧的患者进行调整后的逻辑回归目标作为参考。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：入院时的主要人群特征为：年龄，64 (54-73) 岁；80% 为男性；90% 可电击节律；恢复自主循环的时间为 18 (12-26) 分钟。与有高血压和自由氧目标的患者相比，血压和自由氧目标的患者发生 AKI 的风险增加（84/193 [44%] 对比 56/187 [30%]；调整后的比值比为 1.87 [95% CI , 1.21-2.89])。多项Logistic回归显示，AKI风险增加仅与轻度AKI（KDIGO 1期）相关。其他组AKI风险无差异。住院期间血浆肌酐仍然较高在低血压和自由氧目标组中，但在 6 个月和 12 个月的随访中，各组之间没有差异。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在院外心脏骤停后复苏的昏迷患者中，分配到低平均动脉血压和自由氧目标组合的患者发生轻度 AKI 的风险显着增加。就更严重的 AKI 阶段或其他与肾脏相关的不良后果而言，肌酐在出院 1 年后已恢复正常。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：网址：https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验：gov；唯一标识符：NCT03141099。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37791480/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37791480</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066012>10.1161/CIRCULATIONAHA.123.066012</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37791480</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator>塞巴斯蒂安·布尔·拉斯穆森</dc:creator><dc:creator>卡罗琳·科肖姆·杰普森</dc:creator><dc:creator>杰斯帕·凯尔加德</dc:creator><dc:creator>克里斯蒂安·哈萨格</dc:creator><dc:creator>亨里克·施密特</dc:creator><dc:creator>西蒙·莫尔斯特罗姆</dc:creator><dc:creator>拉斯穆斯·保林·贝斯克</dc:creator><dc:creator>约翰内斯·格兰德</dc:creator><dc:creator>汉尼·伯格·拉文</dc:creator><dc:creator>马蒂尔德·温特-詹森</dc:creator><dc:creator>马丁·阿比尔德·斯坦加德·迈耶</dc:creator><dc:creator>雅各布·艾弗·默勒</dc:creator><dc:date>2023-10-04</dc:date><dc:source>循环</dc:source><dc:title>心脏骤停后肾损伤的血压和氧气目标</dc:title><dc:identifier>下午：37791480</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066012</dc:identifier></item><item><title>表观遗传平衡确保 MLL 扩增和重排的机械控制</title><link/>https://pubmed.ncbi.nlm.nih.gov/37788669/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description> MLL/KMT2A 扩增和易位在婴儿、成人和治疗诱发的白血病中普遍存在。然而，这些改变的分子贡献者尚不清楚。在这里，我们证明组蛋白 H3 赖氨酸 9 单甲基化和二甲基化 (H3K9me1 /2) MLL/KMT2A 基因座的平衡调节这些扩增和重排。这种平衡由赖氨酸脱甲基酶 KDM3B 和甲基转移酶 G9a/EHMT2 之间的串扰控制。KDM3B 耗尽会增加 H3K9me1/2 水平并... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 29 日：S0092-8674(23)01028-0. doi: 10.1016/j.cell.2023.09.009. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MLL/KMT2A 扩增和易位在婴儿、成人和治疗诱发的白血病中普遍存在。然而，这些改变的分子贡献者尚不清楚。在这里，我们证明组蛋白 H3 赖氨酸 9 单甲基化和二甲基化 (H3K9me1 /2) MLL/KMT2A 位点的平衡调节这些扩增和重排。这种平衡由赖氨酸脱甲基酶 KDM3B 和甲基转移酶 G9a/EHMT2 之间的串扰控制。KDM3B 耗尽会增加 H3K9me1/2 水平并减少 MLL/KMT2A 位点的 CTCF 占用，反过来促进扩增和重排。耗尽 CTCF 也足以产生这些局灶性改变。此外，化疗药物阿霉素 (Dox) 与治疗诱导的白血病相关并促进 MLL/KMT2A 扩增和重排，抑制 KDM3B 和 CTCF 蛋白水平KDM3B 和 CTCF 过表达可挽救 Dox 诱导的 MLL/KMT2A 改变。人类细胞或小鼠中的 G9a 抑制也抑制伴随 Dox 治疗的 MLL/KMT2A 事件。因此，MLL/KMT2A 扩增和重排是由表观遗传调节因子控制的，这些调节因子是易于处理的药物靶点，有临床意义。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37788669/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37788669</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.09.009>10.1016/j.cell.2023.09.009</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37788669</guid><pubDate> Tue, 03 Oct 2023 06:00:00 -0400</pubDate><dc:creator>扎克·H·格雷</dc:creator><dc:creator>达马扬提·查克拉博蒂</dc:creator><dc:creator>鲁本·R·杜特韦勒</dc:creator><dc:creator>古尔纳兹·D·阿列克巴耶娃</dc:creator><dc:creator>塞多纳·E·墨菲</dc:creator><dc:creator>卡什切塔尔</dc:creator><dc:creator>费吉</dc:creator><dc:creator>本杰明·弗曼</dc:creator><dc:creator>麦迪逊·A·霍纳</dc:creator><dc:creator>王震天</dc:creator><dc:creator>辛西娅·迈尔斯</dc:creator><dc:creator>孙仁红</dc:creator><dc:creator>胡米特·卡尼斯坎</dc:creator><dc:creator>莫妮卡·玛丽亚·托马</dc:creator><dc:creator>埃琳娜·邦达连科</dc:creator><dc:creator>约翰·N·桑托罗</dc:creator><dc:creator>克里斯托弗·米兰达</dc:creator><dc:creator>梅根·E·迪林厄姆</dc:creator><dc:creator>唐然</dc:creator><dc:creator>或戈扎尼</dc:creator><dc:creator>建金</dc:creator><dc:creator>托马斯·斯科斯基</dc:creator><dc:creator>吉汉吉尔·杜伊</dc:creator><dc:creator>李海燕</dc:creator><dc:creator>鲁斯兰·萨德列耶夫</dc:creator><dc:creator>乔纳森·R·惠斯坦</dc:creator><dc:date>2023-10-03</dc:date><dc:source>细胞</dc:source><dc:title>表观遗传平衡确保 MLL 扩增和重排的机械控制</dc:title><dc:identifier>下午:37788669</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.09.009</dc:identifier></item><item><title>无序区域通过凝结和伙伴招募来控制 cBAF 活性</title><link/>https://pubmed.ncbi.nlm.nih.gov/37788668/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description>本质无序区域 (IDR) 占整个核蛋白含量的很大一部分。普遍的教条是 IDR 参与非特异性相互作用，因为它们很少受到进化选择的限制。在这里，我们证明凝聚体形成和异型相互作用是不同的，并且mSWI/SNF 染色质重塑器 cBAF 的 ARID1A/B 亚基内 IDR 的可分离特征，并在每个基础上建立不同的“序列语法”... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 29 日：S0092-8674(23)00965-0. doi: 10.1016/j.cell.2023.08.032. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">本质无序区域 (IDR) 占整个核蛋白含量的很大一部分。普遍的教条是 IDR 参与非特异性相互作用，因为它们很少受到进化选择的限制。在这里，我们证明凝聚体形成和异型相互作用是不同的，并且mSWI/SNF 染色质重塑器 cBAF 的 ARID1A/B 亚基内 IDR 的可分离特征，并在每个贡献的基础上建立不同的“序列语法”。缩合由均匀分布的酪氨酸残基驱动，伙伴相互作用由非随机介导富含丙氨酸、甘氨酸和谷氨酰胺残基的区块。这些特征集中了特定的 cBAF 蛋白质-蛋白质相互作用网络，对于染色质定位和活性至关重要。重要的是，ARID1B IDR 序列语法中与人类疾病相关的扰动会破坏细胞中的 cBAF 功能。 ，这些数据确定了 IDR 对染色质重塑的贡献，并解释了相分离如何提供一种机制，通过该机制实现基因组定位和功能伙伴招募。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37788668/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37788668</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.032>10.1016/j.cell.2023.08.032</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37788668</guid><pubDate> Tue, 03 Oct 2023 06:00:00 -0400</pubDate><dc:creator>阿金基亚·帕蒂尔</dc:creator><dc:creator>艾米·R·斯特罗姆</dc:creator><dc:creator>若昂·保罗</dc:creator><dc:creator>克莱顿·科林斯</dc:creator><dc:creator>基尔斯滕·M·拉夫</dc:creator><dc:creator>申珉京</dc:creator><dc:creator>阿克谢·桑卡</dc:creator><dc:creator>凯西·塞万提斯</dc:creator><dc:creator>托比亚斯·沃尔</dc:creator><dc:creator>杰西卡·D·圣洛朗</dc:creator><dc:creator>徐女士</dc:creator><dc:creator>林赛·贝克尔</dc:creator><dc:creator>史蒂文·P·吉吉</dc:creator><dc:creator>罗希特·V·帕普</dc:creator><dc:creator>克利福德·P·布朗文</dc:creator><dc:creator>西加尔·卡多克</dc:creator><dc:date>2023-10-03</dc:date><dc:source>细胞</dc:source><dc:title>无序区域通过凝结和伙伴招募来控制 cBAF 活性</dc:title><dc:identifier>下午：37788668</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.032</dc:identifier></item><item><title>减少对缺失 NSTEMI 的担忧，需要进行更多前瞻性随机对照试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37787622/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 3 日：ehad646。doi：10.1093/eurheartj/ehad646。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37787622/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37787622</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad646>10.1093/eurheartj/ehad646</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37787622</guid><pubDate> Tue, 03 Oct 2023 06:00:00 -0400</pubDate><dc:creator>西里尔·科迈罗</dc:creator><dc:creator>西澳戈阿里斯艺术学院</dc:creator><dc:creator>尼尔斯·范·罗延</dc:creator><dc:date>2023-10-03</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>减少对缺失 NSTEMI 的担忧，需要进行更多前瞻性随机对照试验</dc:title><dc:identifier>下午:37787622</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad646</dc:identifier></item><item><title>院前进行单次心肌肌钙蛋白测量时，担心会漏诊非 ST 段抬高型心肌梗死</title><link/>https://pubmed.ncbi.nlm.nih.gov/37787616/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 3 日：ehad642。doi：10.1093/eurheartj/ehad642。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37787616/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37787616</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad642>10.1093/eurheartj/ehad642</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37787616</guid><pubDate> Tue, 03 Oct 2023 06:00:00 -0400</pubDate><dc:creator>乔纳斯·格莱泽</dc:creator><dc:creator>佩德罗·洛佩斯-阿亚拉</dc:creator><dc:creator>克里斯蒂安·穆勒</dc:creator><dc:date>2023-10-03</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>院前进行单次心肌肌钙蛋白测量时，担心会漏诊非 ST 段抬高型心肌梗死</dc:title><dc:identifier>下午：37787616</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad642</dc:identifier></item><item><title>冠状动脉内递送人心脏祖细胞的细胞外囊泡可减少猪急性心肌梗死的梗死面积</title><link/>https://pubmed.ncbi.nlm.nih.gov/37787585/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 3 日：ehad636。doi：10.1093/eurheartj/ehad636。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37787585/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37787585</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad636>10.1093/eurheartj/ehad636</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37787585</guid><pubDate> Tue, 03 Oct 2023 06:00:00 -0400</pubDate><dc:creator>马克西米利安·埃默特</dc:creator><dc:creator>雅各布·布勒罗</dc:creator><dc:creator>佩特拉·沃林特</dc:creator><dc:creator>莫妮卡·希尔布</dc:creator><dc:creator>加布里埃拉·安德里奥洛</dc:creator><dc:creator>卡罗琳娜·巴尔比</dc:creator><dc:creator>埃琳娜·普罗瓦西</dc:creator><dc:creator>露西娅·图尔凯托</dc:creator><dc:creator>玛丽娜·拉德里扎尼</dc:creator><dc:creator>蒂莫·Z·纳扎里-沙夫蒂</dc:creator><dc:creator>尼古拉·切萨罗维奇</dc:creator><dc:creator>塞巴斯蒂安·纽伯</dc:creator><dc:creator>福尔克马尔·法尔克</dc:creator><dc:creator>西蒙·霍尔斯特鲁普</dc:creator><dc:creator>雷扬·赫梅茨伯格</dc:creator><dc:creator>玛丽安·庆吉斯</dc:creator><dc:creator>卢西奥·巴里莱</dc:creator><dc:creator>朱塞佩·瓦萨利</dc:creator><dc:date>2023-10-03</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>冠状动脉内递送人心脏祖细胞的细胞外囊泡可减少猪急性心肌梗死的梗死面积</dc:title><dc:identifier>下午：37787585</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad636</dc:identifier></item><item><title>发酵食品和饮料对心血管的益处：仍有争议</title><link/>https://pubmed.ncbi.nlm.nih.gov/37783744/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 10 月 2 日。doi：10.1038/s41569-023-00938-3。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37783744/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37783744</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00938-3>10.1038/s41569-023-00938-3</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37783744</guid><pubDate> Mon, 02 Oct 2023 06:00:00 -0400</pubDate><dc:creator>拉蒙·埃斯特鲁奇</dc:creator><dc:creator>罗莎·M·拉穆埃拉-拉文托斯</dc:creator><dc:date>2023-10-02</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>发酵食品和饮料对心血管的益处：仍有争议</dc:title><dc:identifier>下午：37783744</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00938-3</dc:identifier></item><item><title>高海拔心血管生理学和病理生理学</title><link/>https://pubmed.ncbi.nlm.nih.gov/37783743/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description>氧气对细胞代谢至关重要，因此，高原缺氧会影响所有生理功能。急性缺氧会激活肾上腺素能系统，诱发心动过速，而缺氧肺血管收缩会增加肺动脉压力。在低氧浓度下暴露几天后，自主神经系统适应，心动过速减少，从而保护心肌免受高能量消耗。永久暴露... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 10 月 2 日。doi：10.1038/s41569-023-00924-9。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">氧气对细胞代谢至关重要，因此，高原缺氧会影响所有生理功能。急性缺氧会激活肾上腺素能系统，诱发心动过速，而缺氧肺血管收缩会增加肺动脉压力。在低氧浓度下暴露几天后，自主神经系统适应，心动过速减少，从而保护心肌免受高能量消耗。长期暴露在高海拔地区会导致红细胞生成，如果过多，可能是有害的，并导致慢性高山病，通常与肺动脉高压和心力衰竭有关。遗传不同的人口和地理区域可能会导致慢性高山病患病率的差异。心血管对缺氧的适应提供了细胞和全身水平氧气供应调节的显着模型。快速暴露在高海拔地区可能会产生不利影响心血管疾病患者。然而，间歇性、中度缺氧可能有助于治疗某些心血管疾病，如冠心病和心力衰竭。本综述的目的是帮助医生了解心血管对缺氧的反应，并了解概述了他们可以向希望前往高海拔目的地的心血管疾病患者提供的一些建议。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37783743/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37783743</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00924-9>10.1038/s41569-023-00924-9</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37783743</guid><pubDate> Mon, 02 Oct 2023 06:00:00 -0400</pubDate><dc:creator>让-保罗·里查莱特</dc:creator><dc:creator>埃里克·赫曼德</dc:creator><dc:creator>弗朗索瓦·J·卢西埃</dc:creator><dc:date>2023-10-02</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>高海拔心血管生理学和病理生理学</dc:title><dc:identifier>下午:37783743</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00924-9</dc:identifier></item><item><title>心血管护理的基于价值的支付：触及问题的核心</title><link/>https://pubmed.ncbi.nlm.nih.gov/37782698/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 10 月 3 日；148(14):1084-1086. doi: 10.1161/CIRCULATIONAHA.123.065661. Epub 2023 年 10 月 2 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37782698/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37782698</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065661>10.1161 / CIRCULATIONAHA.123.065661</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37782698</guid><pubDate> Mon, 02 Oct 2023 06:00:00 -0400</pubDate><dc:creator>里希·K·瓦德拉</dc:creator><dc:date>2023-10-02</dc:date><dc:source>循环</dc:source><dc:title>心血管护理的基于价值的支付：触及问题的核心</dc:title><dc:identifier>下午:37782698</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065661</dc:identifier></item><item><title>获得性因子 VIII 缺乏症导致的出血和心肌梗死</title><link/>https://pubmed.ncbi.nlm.nih.gov/37782697/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 10 月 3 日；148(14):1127-1133. doi: 10.1161/CIRCULATIONAHA.123.063904. Epub 2023 年 10 月 2 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37782697/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37782697</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063904>10.1161/CIRCULATIONAHA.123.063904</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37782697</guid><pubDate> Mon, 02 Oct 2023 06:00:00 -0400</pubDate><dc:creator>约瑟夫·M·金</dc:creator><dc:creator>罗伯特·M·斯特恩</dc:creator><dc:creator>布拉德利·马龙</dc:creator><dc:date>2023-10-02</dc:date><dc:source>循环</dc:source><dc:title>获得性因子 VIII 缺乏症导致的出血和心肌梗死</dc:title><dc:identifier>下午:37782697</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.063904</dc:identifier></item><item><title>慢性冠状动脉粥样硬化患者开始抗炎治疗的时机已经到来</title><link/>https://pubmed.ncbi.nlm.nih.gov/37782696/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 10 月 3 日；148(14):1071-1073.doi: 10.1161/CIRCULATIONAHA.123.066510.Epub 2023 年 10 月 2 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37782696/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37782696</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066510>10.1161 / CIRCULATIONAHA.123.066510</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37782696</guid><pubDate> Mon, 02 Oct 2023 06:00:00 -0400</pubDate><dc:creator>保罗·M·里德克</dc:creator><dc:date>2023-10-02</dc:date><dc:source>循环</dc:source><dc:title>慢性冠状动脉粥样硬化患者开始抗炎治疗的时机已经到来</dc:title><dc:identifier>下午:37782696</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066510</dc:identifier></item><item><title>心源性休克研究和机械循环支持装置的标准化定义：休克学术研究联盟 (SHARC) 的科学专家小组</title><link/>https://pubmed.ncbi.nlm.nih.gov/37782695/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description>休克学术研究联盟是一个多方利益相关者团体，包括来自美国食品和药物管理局以及其他政府机构、行业和付款人的代表，旨在制定实用的共识定义，有助于评估招募心源性休克患者的临床试验，包括评估机械循环支持装置的试验。2020 年至 2022 年期间召开了几次面对面和虚拟会议，讨论……的必要性。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 10 月 3 日；148(14):1113-1126. doi: 10.1161/CIRCULATIONAHA.123.064527. Epub 2023 年 10 月 2 日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">休克学术研究联盟是一个多方利益相关者团体，包括来自美国食品和药物管理局以及其他政府机构、行业和付款人的代表，旨在制定实用的共识定义，有助于评估招募心源性休克患者的临床试验，包括评估机械循环支持装置的试验。2020 年至 2022 年期间召开了多次现场会议和虚拟会议，讨论是否需要制定评估心源性休克患者临床试验中的机械循环支持装置所需的标准化定义。专家小组确定通过进行文献综述（包括以前的临床试验）来了解关键概念和主题，同时认识到当前的挑战以及推进循证实践和统计分析以支持未来临床试验的必要性。对于每个类别，指定一位主要（主要）作者来执行文献检索并起草拟议的定义，并提交给小组。根据专家小组会议的反馈，对这些定义进行进一步修改，直至达成共识。本手稿总结了专家小组的建议，重点关注结果定义，包括功效和安全性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37782695/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37782695</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064527>10.1161/CIRCULATIONAHA.123.064527</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37782695</guid><pubDate> Mon, 02 Oct 2023 06:00:00 -0400</pubDate><dc:creator>罗恩·瓦克斯曼</dc:creator><dc:creator>莫希特·帕胡贾</dc:creator><dc:creator>肖恩·范·迪彭</dc:creator><dc:creator>阿拉斯泰尔·G·普劳德福特</dc:creator><dc:creator>大卫·莫罗</dc:creator><dc:creator>欧内斯特·斯皮策</dc:creator><dc:creator>格雷厄姆·尼科尔</dc:creator><dc:creator>迈伦·L·韦斯费尔特</dc:creator><dc:creator>莫罗·莫斯库奇</dc:creator><dc:creator>帕特里克·R·劳勒</dc:creator><dc:creator>亚历山大·梅巴扎</dc:creator><dc:creator>范艾迪</dc:creator><dc:creator>尼尔·W·迪克特</dc:creator><dc:creator>马克·萨姆斯基</dc:creator><dc:creator>罗伯特·科莫斯</dc:creator><dc:creator>伊莱安娜·L·皮纳</dc:creator><dc:creator>布拉姆·祖克曼</dc:creator><dc:creator>安德鲁·法布</dc:creator><dc:creator>约翰·S·萨皮斯坦</dc:creator><dc:creator>查尔斯·西蒙顿</dc:creator><dc:creator>尼克·EJ·韦斯特</dc:creator><dc:creator>阿卜杜拉·达姆鲁吉</dc:creator><dc:creator>伊恩·吉尔克里斯特</dc:creator><dc:creator>乌韦·泽梅尔</dc:creator><dc:creator>霍尔格·蒂勒</dc:creator><dc:creator>唐纳德·E·卡特利普</dc:creator><dc:creator>米切尔·克鲁科夫</dc:creator><dc:creator>威廉·T·亚伯拉罕</dc:creator><dc:date>2023-10-02</dc:date><dc:source>循环</dc:source><dc:title>心源性休克研究和机械循环支持装置的标准化定义：休克学术研究联盟 (SHARC) 的科学专家小组</dc:title><dc:identifier>下午:37782695</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064527</dc:identifier></item><item><title> BRCC3 介导的 NLRP3 去泛素化促进 &lt;em>;Tet2&lt;/em>; 克隆造血中炎症小体激活和动脉粥样硬化</title><link/>https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231004180813&amp;v=2.17.9.post6+86293ac<description>结论：高胆固醇血症和 TET2 缺乏症集中在由 JNK1 激活和 BRCC3 介导的 NLRP3 去泛素化介导的 NLRP3 炎性体激活的共同途径上，对 TET2 CH 心血管疾病的预防具有潜在的治疗意义。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 10 月 2 日。doi：10.1161/CIRCULATIONAHA.123.065344。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：克隆性造血（CH）已成为动脉粥样硬化性心血管疾病的独立危险因素，巨噬细胞炎症小体的激活是潜在的潜在机制。NLRP3（NLR家族含有pyrin结构域3）炎症小体在促进小鼠动脉粥样硬化中发挥着关键作用。 <i>Tet2</i> CH 模型，而在 CANTOS 中抑制炎症体产物白介素-1β 似乎对<i>TET2</i> CH 患者特别有益（心血管风险降低研究 [减少复发性主要心血管疾病事件]）。 <i>TET2</i>是一种表观遗传修饰剂，可减少启动子甲基化。然而，TET2（Tet 甲基胞嘧啶双加氧酶 2）缺陷时巨噬细胞 NLRP3 炎症小体激活的机制以及与表观遗传修饰的潜在联系尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们使用负载胆固醇的 TET2 缺陷型小鼠和胚胎干细胞来源的同基因人类巨噬细胞来评估体外 NLRP3 炎性小体激活的机制，并使用高胆固醇血症<i>Ldlr</i> <sup>- <i>/</i> -</sup>小鼠模拟<i>TET2</i> CH 来评估 NLRP3 炎性小体激活在动脉粥样硬化中的作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：小鼠巨噬细胞中的<i>Tet2</i>缺陷与细胞培养中的胆固醇负荷和体内高胆固醇血症协同作用，增加 JNK1（c-Jun N 端激酶 1）磷酸化和 NLRP3 炎性体激活。 <i>Dusp10</i>启动子甲基化的主动 Tet1-deadCas9 靶向编辑消除了<i>Tet2</i>缺陷型巨噬细胞中胆固醇诱导的炎症小体激活<i>。JNK1</i>信号传导增加导致 NLRP3 去泛素化并被去泛素化酶 BRCC3（含<i>BRCA1/BRCA2</i>的复合亚基 3）激活。加速动脉粥样硬化和<i>Tet2</i> CH 小鼠的中性粒细胞胞外陷阱形成 (NETosis) 可被 BRCC3 去泛素酶抑制剂全霉素以及 Abro1（含 BRCC3 的胞质复合物中的重要支架蛋白）的造血缺陷所逆转。人<i>TET2</i> <sup>- <i>/</i> -</sup>巨噬细胞表现出 JNK1 增加NLRP3 炎性体激活，尤其是在胆固醇负荷后，可通过全霉素治疗逆转，表明与人类相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：高胆固醇血症和 TET2 缺乏症集中在由 JNK1 激活和 BRCC3 介导的 NLRP3 去泛素化介导的 NLRP3 炎性体激活的共同途径上，对<i>TET2</i> CH 心血管疾病的预防具有潜在的治疗意义。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37781816</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065344>10.1161/CIRCULATIONAHA.123.065344</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37781816</guid><pubDate> Mon, 02 Oct 2023 06:00:00 -0400</pubDate><dc:creator>穆斯塔法·亚辛卡亚</dc:creator><dc:creator>刘文丽</dc:creator><dc:creator>利·安妮·托马斯</dc:creator><dc:creator>马尔戈扎塔·奥尔谢斯卡</dc:creator><dc:creator>童晓</dc:creator><dc:creator>桑德拉·阿布拉莫维奇</dc:creator><dc:creator>埃里尼·P·帕帕佩特鲁</dc:creator><dc:creator>马里特·韦斯特特普</dc:creator><dc:creator>王楠</dc:creator><dc:creator>伊拉·塔巴斯</dc:creator><dc:creator>艾伦·R·高尔</dc:creator><dc:date>2023-10-02</dc:date><dc:source> Circulation</dc:source><dc:title> BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in &lt;em>;Tet2&lt;/em>; Clonal Hematopoiesis</dc:title><dc:identifier> pmid:37781816</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065344</dc:identifier></item><item><title> Association Between Mental Health Burden, Clinical Presentation, and Outcomes in Individuals With Symptomatic Peripheral Artery Disease: A Scientific Statement From the American Heart Association</title><link/> https://pubmed.ncbi.nlm.nih.gov/37781785/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231004180813&amp;v=2.17.9.post6+86293ac<description> Along with the rising burden of peripheral artery disease (PAD), mental health concerns are increasingly being recognized as a comorbidity to address in the chronic disease management of symptomatic PAD. Apart from a high prevalence of comorbid mental health conditions, the role of pain and changing health behaviors and the broader impacts of illness and adaptation to living with PAD require specialized behavioral health expertise. This scientific statement builds a case that this expertise... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Oct 2. doi: 10.1161/CIR.0000000000001178. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Along with the rising burden of peripheral artery disease (PAD), mental health concerns are increasingly being recognized as a comorbidity to address in the chronic disease management of symptomatic PAD. Apart from a high prevalence of comorbid mental health conditions, the role of pain and changing health behaviors and the broader impacts of illness and adaptation to living with PAD require specialized behavioral health expertise. This scientific statement builds a case that this expertise should be integrated within the multidisciplinary PAD team. Furthermore, areas such as cognitive dysfunction and palliative care are highlighted as needing psychological interventions. Although much of the evidence of the efficacy of psychological and psychotropic interventions has been extrapolated from other cardiovascular populations, evidence for the role of psychological interventions for behavior change, for example, uptake of exercise regimens, is increasingly being accrued within PAD. Areas for behavioral health needs and interactions with PAD treatment are discussed, including the use of opioids, depression management, anxiety and stress reduction interventions, the use of benzodiazepines and antidepressants, smoking cessation, rehabilitation trajectories after amputation, and the role of cognitive decline for PAD treatment and outcomes. A case summary highlights the stigma around mental health and vascular disease and the fragmentation of care. This scientific statement provides remarks for building a road map for integrated behavioral PAD care and potential solutions to overcome these barriers. Instrumental to reaching these changes are interprofessional advocacy efforts and initiatives that help break down the stigma around mental health and promote evidence-based collaborative, nonhierarchical, and multidisciplinary PAD care.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37781785/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37781785</a> | DOI: <a href=https://doi.org/10.1161/CIR.0000000000001178>10.1161/CIR.0000000000001178</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37781785</guid><pubDate> Mon, 02 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Kim G Smolderen</dc:creator><dc:creator> Zainab Samaan</dc:creator><dc:creator> Carole Decker</dc:creator><dc:creator> Tracie Collins</dc:creator><dc:creator> Ronald M Lazar</dc:creator><dc:creator> Nathan K Itoga</dc:creator><dc:creator> Carlos Mena-Hurtado</dc:creator><dc:creator> American Heart Association Council on Peripheral Vascular Disease; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Lifestyle and Cardiometabolic Health; and Council on Quality of Care and Outcomes Research</dc:creator><dc:date> 2023-10-02</dc:date><dc:source> Circulation</dc:source><dc:title> Association Between Mental Health Burden, Clinical Presentation, and Outcomes in Individuals With Symptomatic Peripheral Artery Disease: A Scientific Statement From the American Heart Association</dc:title><dc:identifier> pmid:37781785</dc:identifier><dc:identifier> doi:10.1161/CIR.0000000000001178</dc:identifier></item><item><title> Focus on heart failure and cardiomyopathies: new ESC Guidelines and key meta-analyses</title><link/> https://pubmed.ncbi.nlm.nih.gov/37778030/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231004180813&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Oct 1;44(37):3487-3491. doi: 10.1093/eurheartj/ehad647.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37778030/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37778030</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad647>10.1093/eurheartj/ehad647</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37778030</guid><pubDate> Sun, 01 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Filippo Crea</dc:creator><dc:date> 2023-10-01</dc:date><dc:source> European heart journal</dc:source><dc:title> Focus on heart failure and cardiomyopathies: new ESC Guidelines and key meta-analyses</dc:title><dc:identifier> pmid:37778030</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad647</dc:identifier></item><item><title> Understanding T2MI: Thank Goodness for the Women</title><link/> https://pubmed.ncbi.nlm.nih.gov/37777948/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231004180813&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Sep 18:S0735-1097(23)06470-7. doi: 10.1016/j.jacc.2023.08.021. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37777948/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37777948</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.08.021>10.1016/j.jacc.2023.08.021</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37777948</guid><pubDate> Sun, 01 Oct 2023 06:00:00 -0400</pubDate><dc:creator> C Noel Bairey Merz</dc:creator><dc:creator> Martha Gulati</dc:creator><dc:creator> Janet Wei</dc:creator><dc:date> 2023-10-01</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Understanding T2MI: Thank Goodness for the Women</dc:title><dc:identifier> pmid:37777948</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.021</dc:identifier></item><item><title> Coronary Computed Tomographic Angiography With Fractional Flow Reserve in Patients With Type 2 Myocardial Infarction</title><link/> https://pubmed.ncbi.nlm.nih.gov/37777947/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231004180813&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Among individuals with adjudicated T2MI, CAD was prevalent, but the majority of patients had nonobstructive CAD. Mediators of ischemia are likely multifactorial in this population. (Defining the Prevalence and Characteristics of Coronary Artery Disease Among Patients with Type 2 Myocardial Infarction using CT-FFR [DEFINE TYPE 2 MI]; NCT04864119). </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Sep 18:S0735-1097(23)06469-0. doi: 10.1016/j.jacc.2023.08.020. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Type 2 myocardial infarction (T2MI) related to a supply/demand imbalance of coronary blood flow is common and associated with poor prognosis. Coronary artery disease (CAD) may predispose some individuals to T2MI and contribute to its high rate of recurrent cardiovascular events. Little is known about the presence and extent of CAD in this population. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: The goal of this study was to evaluate the presence and characteristics of CAD among patients with T2MI. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: In this prospective study, consecutive eligible individuals with Fourth Universal Definition of Myocardial Infarction criteria for T2MI were enrolled. Participants underwent coronary computed tomography angiography (CTA), fractional flow reserve derived with coronary CTA (FFR <sub>CT</sub> ), and plaque volume analyses. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Among 50 participants, 25 (50%) were female, and the mean age was 68.0 ± 11.4 years. Atherosclerotic risk factors were common. Coronary CTA revealed coronary plaque in 46 participants (92%). A moderate or greater stenosis (≥50%) was identified in 42% of participants, and obstructive disease (≥50% left main stenosis or ≥70% stenosis in any other epicardial coronary artery) was present in 26%. Prevalence of obstructive CAD did not differ according to T2MI cause (P = 0.54). A hemodynamically significant focal stenosis identified by FFR <sub>CT</sub> was present in 13 participants (26%). Among participants with a stenosis ≥50% (n = 21), FFR <sub>CT</sub> excluded lesion-specific hemodynamically significant stenosis in 8 cases (38%). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Among individuals with adjudicated T2MI, CAD was prevalent, but the majority of patients had nonobstructive CAD. Mediators of ischemia are likely multifactorial in this population. (Defining the Prevalence and Characteristics of Coronary Artery Disease Among Patients with Type 2 Myocardial Infarction using CT-FFR [DEFINE TYPE 2 MI]; NCT04864119).</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37777947/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231004180813&v=2.17.9.post6+86293ac">37777947</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.08.020>10.1016/j.jacc.2023.08.020</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37777947</guid><pubDate> Sun, 01 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Cian P McCarthy</dc:creator><dc:creator> Sean P Murphy</dc:creator><dc:creator> Daniel K Amponsah</dc:creator><dc:creator> Paula K Rambarat</dc:creator><dc:creator> Claire Lin</dc:creator><dc:creator> Yuxi Liu</dc:creator><dc:creator> Reza Mohebi</dc:creator><dc:creator> Allison Levin</dc:creator><dc:creator> Avanthi Raghavan</dc:creator><dc:creator> Hannah Miksenas</dc:creator><dc:creator> Campbell Rogers</dc:creator><dc:creator> Jason H Wasfy</dc:creator><dc:creator> Ron Blankstein</dc:creator><dc:creator> Brian Ghoshhajra</dc:creator><dc:creator> Sandeep Hedgire</dc:creator><dc:creator> James L Januzzi</dc:creator><dc:date> 2023-10-01</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Coronary Computed Tomographic Angiography With Fractional Flow Reserve in Patients With Type 2 Myocardial Infarction</dc:title><dc:identifier> pmid:37777947</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.020</dc:identifier></item></channel></rss>